Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 3/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | SMO | Q99835 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686387 | 0.85 | OPRK1 (0.38) | OPRK1IDH1IDH2FABP4FABP5 | |
| SCHEMBL31127400 | 0.85 | OPRK1 (0.38) | OPRK1IDH1IDH2FABP4FABP5 | |
| SCHEMBL21166252 | 0.81 | GRM5 (0.40) | IDH1IDH2FABP4FABP5GRM5 | |
| SCHEMBL21143653 | 0.75 | OPRK1 (0.42) | OPRK1IDH1IDH2FABP4FABP5 | |
| SCHEMBL19686376 | 0.73 | IDH1 (0.41) | IDH1IDH2 | |
| SCHEMBL21144356 | 0.72 | ADORA3 (0.34) | IDH1IDH2NAMPTNOS3NOS1 | |
| SCHEMBL31127431 | 0.72 | ADORA3 (0.34) | IDH1IDH2NAMPTNOS3NOS1 | |
| SCHEMBL21165869 | 0.72 | OPRK1 (0.44) | OPRK1 | |
| SCHEMBL21144088 | 0.71 | GPR119 (0.36) | IDH1IDH2NOS3NOS1NOS2 | |
| SCHEMBL31127073 | 0.71 | GPR119 (0.36) | IDH1IDH2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | OPRK1 337/4885IDH1 3017/4885IDH2 2447/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | OPRK1 337/4885IDH1 3017/4885IDH2 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.